ABSTRACT
Objective To evaluate argon-helium cryoablation combined with transcatheter arterial chemoembolization (TACE) in treating advanced hepatocellular carcinoma (HCC). Methods The clinical data of 66 patients with pathologically-proved HCC were retrospectively analyzed. Based on the therapeutic scheme the patients were divided into TACE group (n=31) and combination group (TACE+argon-helium cryoablation, n=35). All the patients were followed up for 5-35 months. The complete remission rate, total effective rate and survival time were evaluated. The short-term and the long-term effectiveness were compared between the two groups. Results Both the complete remission rate and total effective rate of the combination group were significantly higher than those of TACE group (P0.05). Conclusion For the treatment of advanced hepatocellular carcinoma, argon-helium cryoablation combined with TACE can improve the short-term effect and prolong the progression-free survival time, although its exact effectiveness still needs to be confirmed by large sample, multi-central and randomized controlled studies.
ABSTRACT
Eighty elderly patients undergoing elective resection for the prostate were randomly divided into two groups, the levobupivacaine (observe group) and bupivacaine (control group) were used for spinal anesthesia, respectively. The level of sensory block and maintain time were T7±4 and (224 ±28) min in observed group, those in control group were T6±3 and (227 ±30) min, respectively ( both P＞ 0. 05). The mean arterial blood pressure of control group was (71 ±8) -(72 ±8) mm Hg (1 mm Hg = 0. 133 kPa) from 5 to 30 min after injection; meanwhile that of observed group was(75 ± 9) mm Hg (P ＜ 0. 05). The incidences of hypotension and nausea were 10% (4/40) and 0% (0/40) respectively in observe group, and those were 30% (12/40) and 15% (6/40) respectively in control group (both P＜0.05). The results indicate that levobupivacaine and bupivacaine have similar anesthetic effects, but levobupivacaine has fewer side effects and is more suitable for elderly patients.
ABSTRACT
Objective To assess the efficacy of submucosal injection of thiotepa for the prevention of recurrence of superficial bladder cancer. Methods Sixty-six patients with superficial bladder cancer were chosen, they were randomly divided into injection group(33 cases)and control group(33 cases). In injection group, 33 patients had submucosal injection of thiotepa, after 30 minutes resection of bladder tumor were treated by PKRBt, after one week, they were given perfusion 27 mg BCG. In control group, 33 patients after the PKRBt were given perfusion BCG. Results The recurrence rate in injection group was 15.2%, and that of the control group was 27.3%. There was significant difference between the twO group (P<0.05). Con-clusions The submucosal injection of thiotepa , PKRBt and perfusion BCG could prevent tumor recur-rence,it has the following advantage,such as simple , safe, less side effect ,more economical. The submu-cosal injection is a practical method to prevent tumor recurrence and is worth popularizing.